Intralesional therapy for advanced melanoma
نویسندگان
چکیده
منابع مشابه
Intralesional therapy for advanced melanoma: promise and limitation
PURPOSE OF REVIEW Patients with unresectable, multiple or advanced locally/regionally metastatic stage IIIB/C or stage IV M1a melanoma have a high risk for recurrence, progression and metastasis. The article reviews treatment advances for this population. RECENT FINDINGS After promising phase 2 results with Allovectin-7 (velimogene aliplasmid), overall survival in a phase 3 study was shorter ...
متن کاملDevelopments in Intralesional Therapy for Metastatic Melanoma.
BACKGROUND Locoregional advanced melanoma poses a complex clinical challenge that requires a multidisciplinary, patient-centered approach. Numerous agents have been studied for their suitability as intralesional therapy in the past decades, but few have successfully completed phase 3 clinical trial testing. METHODS The relevant medical literature was searched for articles regarding use of int...
متن کاملUpdates in Therapy for Advanced Melanoma.
Cutaneous melanoma is one of the most aggressive forms of skin cancer, and is correlated with a large proportion of skin cancer-related deaths. Therapy for cutaneous melanoma has advanced greatly through careful identification of therapeutic targets and the development of novel immunotherapeutic approaches. The identification of BRAF as well as other driver mutations, have allowed for a special...
متن کاملIntralesional Therapy: Consensus Statements for Best Practices in Administration From the Melanoma Nursing Initiative .
BACKGROUND Talimogene laherparepvec (T-VEC) is the first intralesional therapy for melanoma approved by the U.S. Food and Drug Administration. This oncolytic viral immunotherapy has improved outcomes for patients with locoregional recurrent melanoma and is showing promise in combination with systemic therapies. . OBJECTIVES This article aims to provide oncology nurses with expert guidance on...
متن کاملCytokine-based therapy and biochemotherapy for advanced melanoma.
A variety of immunotherapeutic approaches have shown activity in patients with metastatic melanoma with the best results being observed with interleukin 2 (IL-2). Follow-up data through 2004 confirm the durability of responses produced by the Food and Drug Administration-approved high-dose IL-2 regimen in this patient population. Efforts to develop more tolerable and/or effective IL-2-based tre...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Current Opinion in Oncology
سال: 2015
ISSN: 1040-8746
DOI: 10.1097/cco.0000000000000158